The client wanted to analyse and quantify the effect of their compounds on survival of retinal ganglion cells (RGC) in early-stage organoids.
We ran a comprehensive toxicity study to test the effects of the compounds of interest on wild-type iPSC-derived human retinal organoids at an early stage of differentiation.
Discussions between the client and our experts identified that it was essential for the study to assess toxicity in a specific region of the early retinal organoid microtissues enriched with ganglion cells and therefore use of organoids at an early stage of differentiation.
Given the need for quantitative measurements, we agreed with the client that the study would include TUNEL staining and quantification of TUNEL images for localisation and intensity analysis with a customised Fiji software to perform statistical analysis of apoptotic cells.
We designed a two parts study which was presented and agreed in our Statement of Work.
Part 1: Use of Hoechst staining for the identification of the apoptotic areas within the organoids in the presence of the two test compounds.
Part 2: Quantification of the effect of two compounds and relevant controls through measurement of TUNEL florescence intensity on frozen 10 mm thin organoid sections.
Our scientists carried out the agreed experiments within the agreed timeline providing regular updates to the customer.
The study included the experimental phase, data processing, data analysis and presentation of a detailed data summary.
Output data set:
The study delivered qualitative and quantitative toxicity imaging data for:
6 technical replicates were performed per experimental condition.
The RGC layer and organoid core was distinguished from the outer organoid layer by fluorescent imaging based on Hoechst staining patterns. The images were acquired with the Zeiss Axio Apotome fluorescence microscope (20x objective).
The level of apoptosis was quantified through TUNEL assay using a Zeiss Axio Apotome fluorescence microscope (20X magnification).
Example data:
We delivered a detailed report of the dataset which was shared digitally and discussed over a call.
The study report clearly demonstrated that:
The study showed that the compounds did not accelerate apoptosis in retinal ganglion cells in early-stage organoids, allowing the client to make an informed decision with regards to the safety profile and progression of their compounds.